PhenotYpe Research for ALS ModIfyer Discovery.

• Conditions: ALS, MND, amyotrophic lateral sclerosis

• Registration Number: NL-OMON26294
• Lead Sponsor: niversity Medical Center Utrecht, the NetherlandsVesalius Research Center, VIB, Leuven, BelgiumUniversity Hospital Jena, Germany

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 600

Inclusion Criteria

All patients with ALS.

Exclusion Criteria

N/A

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Report on key molecular drivers in transcriptomic data related to disease progression (month 35);<br /><br>2. Report on key molecular drivers in methylation data related to disease progression (month 35);<br /><br>3. Report on key molecular drivers in proteomic data related to disease progression (month 35);<br /><br>4. Report on longitudinal MRI and MUNIX changes related to disease progression (month 35).

Secondary Outcome Measures

Name	Time	Method
1. Tender document for appropriate SMEs that describes most promising therapeutic targets, based on differential co-expression, co-methylation and co-translation reports;<br /><br>2. Tender document for appropriate SMEs that describes most promising molecular disease progression markers based on those markers that best discriminate between fast and slow progressors.